Add to ORKGTreatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibito
Psoriasis (PSo) is a chronic inflammatory skin disease associated with co-morbidities such as hypert...
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregul...
Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a prolonged ...
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, ...
Copyright © 2015 Peter H. Schafer et al.This is an open access article distributed under theCreative...
Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints, spine, and entheses, whic...
Andrew C Palfreeman, Kay E McNamee, Fiona E McCann The Kennedy Institute of Rheumatology, Nuffield D...
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular inflammato...
Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for t...
Psoriatic arthritis (PsA) is a chronic inflammatoryarthropathy that affects joints and entheses andi...
ABSTRACT. Objective. Apremilast, a specific inhibitor of phosphodiesterase 4, modulates proinflammat...
Apremilast, competitive inhibitor of phosphodiesterase 4 (PDE4), has been recently introduced in the...
Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence of red a...
Psoriasis is a chronic inflammatory skin disease characterized by dysregulation of the immune system...
Objective: to evaluate the efficacy and safety of a selective phosphodiesterase type 4 inhibitor in ...
Psoriasis (PSo) is a chronic inflammatory skin disease associated with co-morbidities such as hypert...
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregul...
Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a prolonged ...
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, ...
Copyright © 2015 Peter H. Schafer et al.This is an open access article distributed under theCreative...
Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints, spine, and entheses, whic...
Andrew C Palfreeman, Kay E McNamee, Fiona E McCann The Kennedy Institute of Rheumatology, Nuffield D...
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular inflammato...
Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for t...
Psoriatic arthritis (PsA) is a chronic inflammatoryarthropathy that affects joints and entheses andi...
ABSTRACT. Objective. Apremilast, a specific inhibitor of phosphodiesterase 4, modulates proinflammat...
Apremilast, competitive inhibitor of phosphodiesterase 4 (PDE4), has been recently introduced in the...
Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence of red a...
Psoriasis is a chronic inflammatory skin disease characterized by dysregulation of the immune system...
Objective: to evaluate the efficacy and safety of a selective phosphodiesterase type 4 inhibitor in ...
Psoriasis (PSo) is a chronic inflammatory skin disease associated with co-morbidities such as hypert...
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregul...
Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a prolonged ...